VivoSeq
Infectious Disease

Tinea

5

Pipeline Programs↗

1

Active Trials↗

3

Companies Involved↗

Tinea is an early-stage landscape with 5 programs across 3 companies. The most active players are Bayer, Novartis, Sebela Pharmaceuticals Development LLC. 5 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

6/100

Mech. Concentration

60/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bayer logo

Bayer

1 program

ApprovedNovartis logo

Novartis

1 program

ApprovedS

Sebela Pharmaceuticals Development LLC

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

2

clinical trials

Completed1 · 50%
Not yet recruiting1 · 50%

Clinical Trials

Trial Activity

An Open Label Pharmacokinetic Study of Naftin for Tinea Corporis
Completed·MMerz North America, Inc.·Phase 4·NCT02466867·27 enrolled
Comparison of Itraconazole With Itraconazole and Isotretinoin in the Treatment Duration, Safety, and Cure Rate in Adult Patients With Tinea Corporis/Cruris: A Randomized Controlled Trial.
Not yet recruiting·PPak Emirates Military Hospital·Approved·NCT07675239·60 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)